ArticleGenes2022
Extension of PERMANOVA to Testing the Mediation Effect of the Microbiome.
Article in Genes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 14 citations in OpenAlex.
- Microbiome mediation analysis: methods, assumptions, and practical considerations.Frontiers in cellular and infection microbiology · 2026Review
- Prominent mediatory role of gut microbiome in the effect of lifestyle on host metabolic phenotypes.Gut microbes · 2025Article
- Oral Dysbiosis Is Associated with the Pathogenesis of Aortic Valve Diseases.Microorganisms · 2025Article
- Decoding the biochemical dialogue: metabolomic insights into soybean defense strategies against diverse pathogens.Science China. Life sciences · 2024Article
- Statistical and computational methods for integrating microbiome, host genomics, and metabolomics data.eLife · 2024Review
- Gender-affirming hormone therapy preserves skeletal maturation in young mice via the gut microbiome.The Journal of clinical investigation · 2024Article
- Education as Risk Factor of Mild Cognitive Impairment: The Link to the Gut Microbiome.The journal of prevention of Alzheimer's disease · 2024Article
- Why Do These Yeasts Smell So Good? Volatile Organic Compounds (VOCs) Produced byMolecules (Basel, Switzerland) · 2023Article
- Comprehensive microbiome causal mediation analysis using MiMed on user-friendly web interfaces.Biology methods & protocols · 2023Article
- Testing microbiome associations with survival times at both the community and individual taxon levels.PLoS computational biology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Recently, we have seen a growing volume of evidence linking the microbiome and human diseases or clinical outcomes, as well as evidence linking the microbiome and environmental exposures. Now comes the time to assess whether the microbiome mediates the effects of exposures on the outcomes, which will enable researchers to develop interventions to modulate outcomes by modifying microbiome compositions. Use of distance matrices is a popular approach to analyzing complex microbiome data that are high-dimensional, sparse, and compositional. However, the existing distance-based methods for mediation analysis of microbiome data, MedTest and MODIMA, only work well in limited scenarios. PERMANOVA is currently the most commonly used distance-based method for testing microbiome associations. Using the idea of inverse regression, here we extend PERMANOVA to test microbiome-mediation effects by including both the exposure and the outcome as covariates and basing the test on the product of their F statistics. This extension of PERMANOVA, which we call PERMANOVA-med, naturally inherits all the flexible features of PERMANOVA, e.g., allowing adjustment of confounders, accommodating continuous, binary, and multivariate exposure and outcome variables including survival outcomes, and providing an omnibus test that combines the results from analyzing multiple distance matrices. Our extensive simulations indicated that PERMANOVA-med always controlled the type I error and had compelling power over MedTest and MODIMA. Frequently, MedTest had diminished power and MODIMA had inflated type I error. Using real data on melanoma immunotherapy response, we demonstrated the wide applicability of PERMANOVA-med through 16 different mediation analyses, only 6 of which could be performed by MedTest and 4 by MODIMA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.